A randomized, double-blind, placebo parallel controlled clinical trial of Bushen Huoxue Decoction for treatment of coronary heart disease with kidney deficiency and blood stasis syndrome

Guang'anmen Hospital, China Academy of Chinese Medical Sciences0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•1. Follow the diagnostic criteria for unstable angina pectoris of coronary heart disease;
•2. Patients who diagnosed with kidney deficiency and blood stasis syndrome by TCM syndromes;
•3. Patients aged between 18 and 80 years;
•4. Patients who voluntarily sign the informed consent.

•1. Severe valvular heart disease, severe neurosis, menopausal syndrome, hyperthyroidism, cervical spondylosis, biliary heart disease, stomach and esophageal reflux and other non-coronary heart disease caused by chest pain;
•2. Poor hypertension control (under drug control, blood pressure >=160/100mmHg at rest and occasionally within a week), severe cardiopulmonary insufficiency (EF<35%), severe arrhythmia (rapid atrial fibrillation, atrial flutter, paroxysmal ventricular tachycardia,atrioventricular block of type II and above, complete bundle branch block);
•3. Complicated with serious primary diseases such as heart, brain, liver, kidney, hematopoietic system, (hepatic function ALT or AST value ?1.5 times the upper limit of normal, patients with abnormal renal function), insulin-dependent type 2 diabetes;
•4. Patients with depression or anxiety;
•5.Pregnant or lactating women;
•6. Patients with malignant tumors;
•7. Patients with allergies and allergies to test drug components;
•8. Patients with poor compliance and low possibility of follow-up;
•9. Participants in other clinical trials within the past month;
•10. Other major diseases or factors that interfere with the completion of the trial or affect the interpretation of the results.

发起方